Meta-analysis finds no consistent link between SGLT2is and amputations

  • Heyward J & al.
  • PLoS One
  • 01/01/2020

  • Miriam Tucker
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • A systematic review/meta-analysis has shown no consistent evidence of sodium-glucose cotransporter 2 inhibitors (SGLT2is) exposure and increased amputation risk.

Why this matters

Study design

  • Meta-analysis included 12 randomized controlled trials (RCTs) of 45,551 participants (n=25,593 receiving SGLT2i, n=600 alternative treatment, n=19,358 placebo).
  • Funding: Monument Analytics.

Key results

  • Random effect meta-analysis of 7 RCTs suggested no statistically significant association between SGLT2i exposure and amputation risk, with evidence of substantial statistical heterogeneity (risk ratio, 1.28; 95% CI, 0.93-1.76; I2=62.0%; P=.12).
  • Fixed-effects analysis showed an increased risk, however, again with statistical heterogeneity (1.27; 95% CI, 1.09-1.48; I2=62%; P=.003).
  • In a subgroup analysis of canagliflozin vs placebo, a statistically significantly increased risk emerged in a fixed-effects meta-analysis (relative risk, 1.59; 95% CI, 1.26-2.01; I2=88%; P=.0001), but no effect with dapagliflozin or empagliflozin.
  • In observational data, study heterogeneity and potential confounding prevented meta-analysis, although two-thirds of comparisons with other drug classes showed a nonsignificant increased amputation risk.

Limitations

  • Limited statistical power to detect rare events.
  • Amputation was not a prespecified outcome in any trial.
  • No individual patient-level data.
  • Considerable heterogeneity across studies.